|
US3539380A
(en)
|
1968-01-08 |
1970-11-10 |
Upjohn Co |
Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms
|
|
GB1573487A
(en)
|
1977-05-23 |
1980-08-28 |
Bristol Myers Co |
Bile acid binding composition
|
|
EP0049500B1
(de)
|
1979-04-30 |
1984-02-22 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Tyrosinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Synthese von Peptiden
|
|
CA1313135C
(en)
|
1987-02-09 |
1993-01-26 |
The Dow Chemical Company |
Cholestyramine composition and process for its preparation
|
|
US5167965A
(en)
|
1987-02-09 |
1992-12-01 |
The Dow Chemical Company |
Palatable cholestyramine granules, tablets and methods for preparation thereof
|
|
US4900757A
(en)
|
1988-12-08 |
1990-02-13 |
Merrell Dow Pharmaceuticals Inc. |
Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
|
|
JP2800242B2
(ja)
|
1989-03-30 |
1998-09-21 |
大正製薬株式会社 |
粒剤の製造方法
|
|
IL95574A
(en)
|
1989-09-09 |
1994-11-11 |
Knoll Ag |
Colestyramine preparation
|
|
DE3930168A1
(de)
|
1989-09-09 |
1991-03-14 |
Knoll Ag |
Verbesserte verabreichungsform fuer colestyramin
|
|
JP2542122B2
(ja)
|
1990-04-18 |
1996-10-09 |
旭化成工業株式会社 |
球状核、球形顆粒およびその製造方法
|
|
NZ240846A
(en)
|
1990-12-06 |
1994-04-27 |
Hoechst Ag |
Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions
|
|
ES2087422T3
(es)
|
1991-12-20 |
1996-07-16 |
Hoechst Ag |
Polimeros y oligomeros de derivados de acidos biliares, procedimiento para su preparacion y su empleo como medicamento.
|
|
JPH05186357A
(ja)
|
1991-12-31 |
1993-07-27 |
Shigeo Ochi |
飲食物消化分解産物吸収抑制手段
|
|
GB9203347D0
(en)
|
1992-02-17 |
1992-04-01 |
Wellcome Found |
Hypolipidaemic compounds
|
|
ES2111092T3
(es)
|
1992-06-12 |
1998-03-01 |
Hoechst Ag |
Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
|
|
US5350584A
(en)
|
1992-06-26 |
1994-09-27 |
Merck & Co., Inc. |
Spheronization process using charged resins
|
|
IL108633A
(en)
|
1993-02-15 |
1998-07-15 |
Wellcome Found |
History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
|
|
IL108634A0
(en)
|
1993-02-15 |
1994-05-30 |
Wellcome Found |
Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
|
|
TW289757B
(https=)
|
1993-05-08 |
1996-11-01 |
Hoechst Ag |
|
|
TW289021B
(https=)
|
1993-05-08 |
1996-10-21 |
Hoechst Ag |
|
|
TW289020B
(https=)
|
1993-05-08 |
1996-10-21 |
Hoechst Sktiengesellschaft |
|
|
EP0624593A3
(de)
|
1993-05-08 |
1995-06-07 |
Hoechst Ag |
Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
|
|
ZA956647B
(en)
|
1994-08-10 |
1997-02-10 |
Wellcome Found |
Hypolipidaemic compounds.
|
|
US5994391A
(en)
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
DK0781278T3
(da)
|
1994-09-13 |
2001-04-17 |
Monsanto Co |
Nye benzothiepiner, som har aktivitet som inhibitorer af ileal galdsyretransport og taurocholatoptagelse
|
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
GB9423172D0
(en)
|
1994-11-17 |
1995-01-04 |
Wellcom Foundation The Limited |
Hypolipidemic benzothiazepines
|
|
US5811388A
(en)
|
1995-06-07 |
1998-09-22 |
Cibus Pharmaceutical, Inc. |
Delivery of drugs to the lower GI tract
|
|
AU724620B2
(en)
|
1996-01-16 |
2000-09-28 |
Sokol, Ronald J Dr. |
Use of antioxidant agents to treat cholestatic liver disease
|
|
DE19608592A1
(de)
|
1996-03-06 |
1997-09-11 |
Hoechst Ag |
Antikörper zur selektiven immunologischen Bestimmung von Gallensäuren in biologischen Matrices
|
|
NZ331813A
(en)
|
1996-03-11 |
2001-03-30 |
G |
Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
ES2306459T3
(es)
|
1996-05-23 |
2008-11-01 |
Novartis Ag |
Prevencion y tratamiento de adenoma colonico o microadenoma colonico mediante acido 6-fluoroursodesoxicolico (6-fudca).
|
|
WO1998003818A1
(de)
|
1996-07-24 |
1998-01-29 |
Zumtobel Staff Gmbh |
Adapter für ein haltemittel, welches zum befestigen einer einbauleuchte in einer einbauöffnung bestimmt ist, oder haltemittel oder einbauleuchte mit einem solchen adapter
|
|
DE19633268A1
(de)
|
1996-08-19 |
1998-02-26 |
Hoechst Ag |
Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung
|
|
GB9704208D0
(en)
|
1997-02-28 |
1997-04-16 |
Glaxo Group Ltd |
Chemical compounds
|
|
MXPA99008417A
(es)
|
1997-03-11 |
2005-02-03 |
Searle & Co |
Terapia de combinacion que emplaza benzotiepinas inhibidoras de transporte de acido biliar ileal e inhibidores de hmg co-a reductasa.
|
|
DE69815180T2
(de)
|
1997-03-14 |
2004-04-29 |
Aventis Pharma Deutschland Gmbh |
Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
CA2290624C
(en)
|
1997-06-06 |
2006-12-05 |
John W. Shell |
Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
|
|
WO1998056757A1
(fr)
|
1997-06-11 |
1998-12-17 |
Sankyo Company, Limited |
Derives de benzylamine
|
|
AUPO763197A0
(en)
|
1997-06-30 |
1997-07-24 |
Sigma Pharmaceuticals Pty Ltd |
Health supplement
|
|
US5900233A
(en)
|
1997-10-16 |
1999-05-04 |
Day; Charles E. |
Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome
|
|
US20030153541A1
(en)
|
1997-10-31 |
2003-08-14 |
Robert Dudley |
Novel anticholesterol compositions and method for using same
|
|
US6369220B1
(en)
|
1997-12-19 |
2002-04-09 |
Jinglin (James T.) Li |
Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides
|
|
GB9800428D0
(en)
|
1998-01-10 |
1998-03-04 |
Glaxo Group Ltd |
Chemical compounds
|
|
KR20010042618A
(ko)
|
1998-04-24 |
2001-05-25 |
후지야마 아키라 |
구아니딘 유도체
|
|
US6221897B1
(en)
|
1998-06-10 |
2001-04-24 |
Aventis Pharma Deutschland Gmbh |
Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
|
|
DE19825804C2
(de)
|
1998-06-10 |
2000-08-24 |
Aventis Pharma Gmbh |
1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
|
|
EP1103552A4
(en)
|
1998-08-07 |
2003-01-15 |
Takeda Chemical Industries Ltd |
BENZOTHIEPINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE
|
|
JP2002533414A
(ja)
|
1998-12-23 |
2002-10-08 |
ジー．ディー．サール エルエルシー |
心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
|
|
EP1140191B1
(en)
|
1998-12-23 |
2002-10-23 |
G.D. Searle LLC. |
Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
|
|
DE69911058T2
(de)
|
1998-12-23 |
2004-06-03 |
G.D. Searle Llc, Chicago |
Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
|
|
CN1342090A
(zh)
|
1998-12-23 |
2002-03-27 |
G·D·瑟尔有限公司 |
适用于心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合
|
|
PL348508A1
(en)
|
1998-12-23 |
2002-05-20 |
Searle Llc |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
|
CA2362147A1
(en)
|
1999-02-12 |
2000-08-17 |
Steve A. Kolodziej |
1,2-benzothiazepines for the treatment of hyperlipidemic diseases
|
|
DE19916108C1
(de)
|
1999-04-09 |
2001-01-11 |
Aventis Pharma Gmbh |
Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
|
|
SE9901387D0
(sv)
|
1999-04-19 |
1999-04-19 |
Astra Ab |
New pharmaceutical foromaulations
|
|
US6287609B1
(en)
|
1999-06-09 |
2001-09-11 |
Wisconsin Alumni Research Foundation |
Unfermented gel fraction from psyllium seed husks
|
|
WO2001034570A1
(en)
|
1999-11-08 |
2001-05-17 |
Sankyo Company, Limited |
Nitrogenous heterocycle derivatives
|
|
GB9927088D0
(en)
|
1999-11-17 |
2000-01-12 |
Secr Defence |
Use of poly(diallylamine) polymers
|
|
AU784722B2
(en)
|
2000-02-18 |
2006-06-01 |
Merck & Co., Inc. |
Aryloxyacetic acids for diabetes and lipid disorders
|
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2001068637A2
(en)
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Method for the preparation of tetrahydrobenzothiepines
|
|
AU2001247331A1
(en)
|
2000-03-10 |
2001-09-24 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
|
US6638498B2
(en)
|
2000-06-30 |
2003-10-28 |
Semorex Inc. |
Molecularly imprinted polymers for the treatment and diagnosis of medical conditions
|
|
US20020183307A1
(en)
|
2000-07-26 |
2002-12-05 |
Tremont Samuel J. |
Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
|
|
FR2812886B1
(fr)
|
2000-08-08 |
2002-11-08 |
Assist Publ Hopitaux De Paris |
Depistage d'un nouveau syndrome hepatique et ses applications
|
|
SE0003766D0
(sv)
|
2000-10-18 |
2000-10-18 |
Astrazeneca Ab |
Novel formulation
|
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2002053548A1
(fr)
|
2000-12-27 |
2002-07-11 |
Banyu Pharmaceutical Co.,Ltd. |
Derives de la benzothiazepine
|
|
US6506921B1
(en)
|
2001-06-29 |
2003-01-14 |
Virginia Tech Intellectual Properties, Inc. |
Amine compounds and curable compositions derived therefrom
|
|
US20040077625A1
(en)
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
|
US20040038862A1
(en)
|
2001-07-30 |
2004-02-26 |
Goodwin Bryan James |
Identification of new therapeutic targets for modulating bile acid synthesis
|
|
GB0121337D0
(en)
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
TWI331143B
(en)
|
2001-09-08 |
2010-10-01 |
Astrazeneca Uk Ltd |
Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them
|
|
US20030199515A1
(en)
|
2001-09-12 |
2003-10-23 |
G.D. Searle, Llc |
Method for the preparation of crystalline tetrahydrobenzothiepines
|
|
MXPA04003524A
(es)
|
2001-11-02 |
2004-07-23 |
Searle Llc |
Compuestos de benzotiepina monofluorados y difluorados novedosos como inhibidores de transporte de acido biliar co-dependiente de sodio apical (asbt) y captacion de taurocolato.
|
|
TW200300349A
(en)
|
2001-11-19 |
2003-06-01 |
Sankyo Co |
A 4-oxoqinoline derivative
|
|
GB0229931D0
(en)
|
2002-12-21 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
|
SE0104334D0
(sv)
|
2001-12-19 |
2001-12-19 |
Astrazeneca Ab |
Therapeutic agents
|
|
JP2005518408A
(ja)
|
2001-12-29 |
2005-06-23 |
ノボ ノルディスク アクティーゼルスカブ |
異常脂肪血症を治療するための、ｇｌｐ−１化合物と他の薬物との組み合わせ使用
|
|
GB0201850D0
(en)
|
2002-01-26 |
2002-03-13 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US20040014806A1
(en)
|
2002-03-08 |
2004-01-22 |
Pharmacia Corporation |
Methods and compositions for lowering levels of blood lipids
|
|
GB0209467D0
(en)
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0213669D0
(en)
|
2002-06-14 |
2002-07-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0216321D0
(en)
|
2002-07-13 |
2002-08-21 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US7312208B2
(en)
|
2002-08-28 |
2007-12-25 |
Asahi Kasei Pharma Corporation |
Quaternary ammonium compounds
|
|
AU2003257578B2
(en)
|
2002-08-28 |
2009-01-22 |
Asahi Kasei Pharma Corporation |
Novel quaternary ammonium compounds
|
|
GB0304194D0
(en)
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2004076657A2
(en)
|
2003-02-28 |
2004-09-10 |
Mcgill University |
Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
|
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
|
WO2005036971A1
(en)
|
2003-10-16 |
2005-04-28 |
Techcom Group, Llc |
Reduced digestible carbohydrate food having reduced blood glucose response
|
|
CN102293773A
(zh)
|
2004-02-27 |
2011-12-28 |
旭化成制药株式会社 |
含有苯并硫氮杂卓和苯并虑平化合物的药物
|
|
TW200533336A
(en)
|
2004-03-02 |
2005-10-16 |
Fujisawa Pharmaceutical Co |
Concomitant drugs
|
|
EP1593671A1
(en)
|
2004-03-05 |
2005-11-09 |
Graffinity Pharmaceuticals AG |
DPP-IV inhibitors
|
|
US20050215882A1
(en)
|
2004-03-23 |
2005-09-29 |
The Regents Of The University Of Michigan |
Noninvasive method to determine fat content of tissues using MRI
|
|
TWI354569B
(en)
|
2004-05-28 |
2011-12-21 |
Bristol Myers Squibb Co |
Coated tablet formulation and method
|
|
US20090131395A1
(en)
|
2005-05-05 |
2009-05-21 |
Microbia, Inc. |
Biphenylazetidinone cholesterol absorption inhibitors
|
|
DE102005033100B3
(de)
|
2005-07-15 |
2007-01-25 |
Sanofi-Aventis Deutschland Gmbh |
Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
|
|
DE102005033099A1
(de)
|
2005-07-15 |
2007-01-18 |
Sanofi-Aventis Deutschland Gmbh |
Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
|
|
CA2622579C
(en)
|
2005-09-20 |
2013-12-31 |
Novartis Ag |
Use of a dpp-iv inhibitor to reduce hypoglycemic events
|
|
US8048413B2
(en)
|
2006-05-17 |
2011-11-01 |
Helene Huguet |
Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
|
|
DE102006053635B4
(de)
|
2006-11-14 |
2011-06-30 |
Sanofi-Aventis Deutschland GmbH, 65929 |
Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
DE102006053636B4
(de)
|
2006-11-14 |
2008-09-18 |
Sanofi-Aventis Deutschland Gmbh |
Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
|
|
JP2010509252A
(ja)
|
2006-11-14 |
2010-03-25 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
改善された特性を有する新規な１，４−ベンゾチエピン−１，１−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物、及びそれらの使用
|
|
DE102006053637B4
(de)
|
2006-11-14 |
2011-06-30 |
Sanofi-Aventis Deutschland GmbH, 65929 |
Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
KR101555716B1
(ko)
|
2007-01-19 |
2015-09-25 |
인터셉트 파마슈티컬즈, 인크. |
Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
|
|
CA2678367C
(en)
|
2007-03-02 |
2014-07-08 |
Farnam Companies, Inc. |
Sustained release compositions using wax-like materials
|
|
US9295677B2
(en)
|
2008-02-26 |
2016-03-29 |
Qing Bile Therapeutics Inc. |
Polyhydroxylated bile acids for treatment of biliary disorders
|
|
WO2010041268A2
(en)
|
2008-09-02 |
2010-04-15 |
Usv Limited |
Crosslinked polymers
|
|
CA2744817C
(en)
|
2008-11-26 |
2020-07-07 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
|
FR2943342B1
(fr)
|
2009-03-20 |
2011-03-04 |
Servier Lab |
Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
|
|
US20110152204A1
(en)
|
2009-12-18 |
2011-06-23 |
Satiogen Pharmaceuticals, Inc. |
Treatment of Obesity or Diabetes with Bile Acid Sequestrants
|
|
JO3131B1
(ar)
|
2010-04-27 |
2017-09-20 |
Glaxosmithkline Llc |
مركبات كيميائية
|
|
EP2575821B1
(en)
|
2010-05-26 |
2015-08-12 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
PL3400944T3
(pl)
|
2010-11-04 |
2020-11-16 |
Albireo Ab |
Inhibitory ibat w leczeniu chorób wątroby
|
|
US20120114588A1
(en)
|
2010-11-08 |
2012-05-10 |
Albireo Ab |
Ibat inhibitors for treatment of metabolic disorders and related conditions
|
|
JP6097695B2
(ja)
|
2010-11-08 |
2017-03-15 |
アルビレオ アクチエボラグ |
Ｉｂａｔ阻害剤および胆汁酸結合剤を含む薬学的組み合わせ
|
|
MX2013005110A
(es)
|
2010-11-08 |
2013-08-21 |
Albireo Ab |
Inhibidores del ibat para el tratamiento de padecimientos metabolicos y condiciones relacionadas.
|
|
CN104023727B
(zh)
|
2011-10-28 |
2017-04-05 |
鲁美纳医药公司 |
用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
|
|
CA2852957C
(en)
|
2011-10-28 |
2020-08-04 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
|
|
CA2872002C
(en)
|
2012-05-07 |
2019-01-15 |
Masayuki Isaji |
Pyrazole derivative and use thereof for medical purposes
|
|
US20140275090A1
(en)
|
2013-03-15 |
2014-09-18 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
|
|
JO3301B1
(ar)
|
2013-04-26 |
2018-09-16 |
Albireo Ab |
تعديلات بلورية على إيلوبيكسيبات
|
|
EP3110507B1
(en)
|
2014-02-27 |
2020-11-18 |
NuSirt Sciences, Inc. |
Compositions and methods for the reduction or prevention of hepatic steatosis
|
|
CN106573033A
(zh)
|
2014-06-25 |
2017-04-19 |
Ea制药株式会社 |
固体制剂及其稳定化方法
|
|
CA2952406A1
(en)
|
2014-06-25 |
2015-12-30 |
Ea Pharma Co., Ltd. |
Solid formulation and method for preventing or reducing coloration thereof
|
|
KR101674806B1
(ko)
|
2014-10-20 |
2016-11-10 |
씨제이헬스케어 주식회사 |
신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
|
|
EP3012252A1
(en)
|
2014-10-24 |
2016-04-27 |
Ferring BV |
Crystal modifications of elobixibat
|
|
US9684018B2
(en)
|
2014-11-19 |
2017-06-20 |
Texas Instruments Incorporated |
Current sense circuit that operates over a wide range of currents
|
|
KR20160061492A
(ko)
|
2014-11-21 |
2016-06-01 |
삼성디스플레이 주식회사 |
휴대용 먼지 센서 및 이를 이용한 휴대전화
|
|
RU2750937C2
(ru)
|
2016-02-09 |
2021-07-06 |
Альбирео Аб |
Пероральный состав холестирамина и его применение
|
|
US10441605B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US10441604B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
|
EP3413877B1
(en)
|
2016-02-09 |
2021-04-07 |
Albireo AB |
Oral cholestyramine formulation and use thereof
|
|
CA3011595C
(en)
|
2016-02-09 |
2024-01-02 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
|
US11350844B2
(en)
|
2016-11-23 |
2022-06-07 |
Mayo Foundation For Medical Education And Research |
System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography
|
|
KR101844184B1
(ko)
|
2017-07-21 |
2018-04-02 |
씨제이헬스케어 주식회사 |
아미노알킬벤조티아제핀 유도체의 용도
|
|
JP2020530448A
(ja)
|
2017-08-09 |
2020-10-22 |
アルビレオ・アクチボラグ |
コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
|
|
CA3071182A1
(en)
|
2017-08-09 |
2019-02-14 |
Albireo Ab |
Cholestyramine pellets, oral cholestyramine formulations and use thereof
|
|
TWI822738B
(zh)
|
2018-03-09 |
2023-11-21 |
瑞典商依洛比克斯公司 |
用於製備1,5-苯并噻氮呯化合物之方法
|
|
US10428109B1
(en)
|
2018-03-09 |
2019-10-01 |
Elobix Ab |
Process for the preparation of 1,5-benzothiazepine compounds
|
|
ES2942443T3
(es)
|
2018-06-05 |
2023-06-01 |
Albireo Ab |
Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
|
|
US10793534B2
(en)
|
2018-06-05 |
2020-10-06 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
|
BR112020024479A2
(pt)
|
2018-06-20 |
2021-03-02 |
Albireo Ab |
hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica
|
|
WO2020016758A1
(en)
*
|
2018-07-16 |
2020-01-23 |
Systagenix Wound Management, Limited |
Nitric oxide producing collagen/orc dressing
|
|
HUE060905T2
(hu)
|
2019-02-06 |
2023-04-28 |
Albireo Ab |
Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként
|
|
US10975045B2
(en)
|
2019-02-06 |
2021-04-13 |
Aibireo AB |
Benzothiazepine compounds and their use as bile acid modulators
|
|
ES2955799T3
(es)
|
2019-02-06 |
2023-12-07 |
Albireo Ab |
Compuestos de benzotiazepina y su uso como moduladores de los ácidos biliares
|
|
US10941127B2
(en)
|
2019-02-06 |
2021-03-09 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
WO2020165758A1
(en)
*
|
2019-02-11 |
2020-08-20 |
Universidade Do Porto |
Device and method for cardiopathies assessment
|
|
PL3923943T3
(pl)
|
2019-02-12 |
2024-12-09 |
Mirum Pharmaceuticals, Inc. |
Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych
|
|
WO2020167985A1
(en)
|
2019-02-15 |
2020-08-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and systems for reducing a pathogen population
|
|
WO2020194531A1
(ja)
|
2019-03-26 |
2020-10-01 |
国立大学法人東北大学 |
血中尿毒症物質の低減剤
|
|
AR120676A1
(es)
|
2019-12-04 |
2022-03-09 |
Albireo Ab |
Compuestos de benzoti(di)azepina y su uso como ácido biliar
|
|
CN114786772B
(zh)
|
2019-12-04 |
2024-04-09 |
阿尔比里奥公司 |
苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
|
ES2973549T3
(es)
|
2019-12-04 |
2024-06-20 |
Albireo Ab |
Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
|
|
TWI867107B
(zh)
|
2019-12-04 |
2024-12-21 |
瑞典商艾爾比瑞歐公司 |
苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
|
|
CA3158181A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
AR120679A1
(es)
|
2019-12-04 |
2022-03-09 |
Albireo Ab |
Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
|
|
TWI877263B
(zh)
|
2019-12-04 |
2025-03-21 |
瑞典商艾爾比瑞歐公司 |
苯并噻二氮呯化合物及其作為膽酸調節劑之用途
|
|
TWI877262B
(zh)
|
2019-12-04 |
2025-03-21 |
瑞典商艾爾比瑞歐公司 |
苯并噻氮呯化合物及其作為膽酸調節劑之用途
|
|
CA3158184A1
(en)
|
2019-12-04 |
2021-08-10 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
WO2022029101A1
(en)
|
2020-08-03 |
2022-02-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
EP4188541B1
(en)
|
2020-08-03 |
2024-12-25 |
Albireo AB |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
JP2023549226A
(ja)
|
2020-11-12 |
2023-11-22 |
アルビレオ エービー |
進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット
|
|
WO2022101379A1
(en)
|
2020-11-12 |
2022-05-19 |
Albireo Ab |
Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
|
|
JP2024500309A
(ja)
|
2020-12-04 |
2024-01-09 |
アルビレオ エービー |
ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用
|
|
TW202313579A
(zh)
|
2021-06-03 |
2023-04-01 |
瑞典商艾爾比瑞歐公司 |
苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
|
|
JP2025516153A
(ja)
|
2022-04-22 |
2025-05-27 |
アルビレオ・アクチボラグ |
Ａｓｂｔ阻害剤の皮下投与
|
|
KR20250022025A
(ko)
|
2022-06-09 |
2025-02-14 |
알비레오 에이비 |
간염 치료
|
|
CN119487013A
(zh)
|
2022-07-05 |
2025-02-18 |
阿尔比里奥公司 |
苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
US20240173333A1
(en)
|
2022-11-03 |
2024-05-30 |
Albireo Ab |
Treating Alagille Syndrome (ALGS)
|
|
AU2023390975A1
(en)
|
2022-12-09 |
2025-06-05 |
Albireo Ab |
Asbt inhibitors in the treatment of renal diseases
|